Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Brain Stimul ; 17(2): 349-361, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38479713

RESUMEN

Motor sequence learning gradually quickens reaction time, suggesting that sequence learning alters motor preparation processes. Interestingly, evidence has shown that preparing sequence movements decreases short intracortical inhibition (SICI) in the contralateral motor cortex (M1), but also that sequence learning alters motor preparation processes in both the contralateral and ipsilateral M1s. Therefore, one possibility is that sequence learning alters the SICI decreases occurring during motor preparation in bilateral M1s. To examine this, two novel hypotheses were tested: unilateral sequence preparation would decrease SICI in bilateral M1s, and sequence learning would alter such bilateral SICI responses. Paired-pulse transcranial magnetic stimulation was delivered over the contralateral and ipsilateral M1s to assess SICI in an index finger muscle during the preparation of sequences initiated by either the right index or little finger. In the absence of sequence learning, SICI decreased in both the contralateral and ipsilateral M1s during the preparation of sequences initiated by the right index finger, suggesting that SICI decreases in bilateral M1s during unilateral motor preparation. As sequence learning progressed, SICI decreased in the contralateral M1 whilst it increased in the ipsilateral M1. Moreover, these bilateral SICI responses were observed at the onset of motor preparation, suggesting that sequence learning altered baseline SICI levels rather than the SICI decreases occurring during motor preparation per se. Altogether, these results suggest that SICI responses in bilateral M1s reflect two motor processes: an acute decrease of inhibition during motor preparation, and a cooperative but bidirectional shift of baseline inhibition levels as sequence learning progresses.


Asunto(s)
Potenciales Evocados Motores , Aprendizaje , Corteza Motora , Inhibición Neural , Estimulación Magnética Transcraneal , Humanos , Corteza Motora/fisiología , Estimulación Magnética Transcraneal/métodos , Masculino , Femenino , Adulto , Potenciales Evocados Motores/fisiología , Aprendizaje/fisiología , Inhibición Neural/fisiología , Electromiografía , Tiempo de Reacción/fisiología , Adulto Joven , Lateralidad Funcional/fisiología , Desempeño Psicomotor/fisiología , Dedos/fisiología , Movimiento/fisiología
2.
J Intellect Disabil Res ; 60(2): 149-55, 2016 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-26018613

RESUMEN

BACKGROUND: We report striking and unanticipated improvements in maladaptive behaviours in Prader-Willi syndrome (PWS) during a trial of vagus nerve stimulation (VNS) initially designed to investigate effects on the overeating behaviour. PWS is a genetically determined neurodevelopmental disorder associated with mild-moderate intellectual disability (ID) and social and behavioural difficulties, alongside a characteristic and severe hyperphagia. METHODS: Three individuals with PWS underwent surgery to implant the VNS device. VNS was switched on 3 months post-implantation, with an initial 0.25 mA output current incrementally increased to a maximum of 1.5 mA as tolerated by each individual. Participants were followed up monthly. RESULTS: Vagal nerve stimulation in these individuals with PWS, within the stimulation parameters used here, was safe and acceptable. However, changes in eating behaviour were equivocal. Intriguingly, unanticipated, although consistent, beneficial effects were reported by two participants and their carers in maladaptive behaviour, temperament and social functioning. These improvements and associated effects on food-seeking behaviour, but not weight, indicate that VNS may have potential as a novel treatment for such behaviours. CONCLUSIONS: We propose that these changes are mediated through afferent and efferent vagal projections and their effects on specific neural networks and functioning of the autonomic nervous system and provide new insights into the mechanisms that underpin what are serious and common problems affecting people with IDs more generally.


Asunto(s)
Agresión/fisiología , Trastornos de Alimentación y de la Ingestión de Alimentos/terapia , Síndrome de Prader-Willi/terapia , Trastorno de la Conducta Social/terapia , Estimulación del Nervio Vago/métodos , Adulto , Composición Corporal , Peso Corporal , Trastornos de Alimentación y de la Ingestión de Alimentos/etiología , Femenino , Humanos , Masculino , Síndrome de Prader-Willi/complicaciones , Trastorno de la Conducta Social/etiología , Resultado del Tratamiento , Estimulación del Nervio Vago/efectos adversos , Adulto Joven
3.
Neuroscience ; 281: 68-76, 2014 Dec 05.
Artículo en Inglés | MEDLINE | ID: mdl-25261686

RESUMEN

In Parkinson's disease (PD), elevated beta (15-35Hz) power in subcortical motor networks is widely believed to promote aspects of PD symptomatology, moreover, a reduction in beta power and coherence accompanies symptomatic improvement following effective treatment with l-DOPA. Previous studies have reported symptomatic improvements that correlate with changes in cortical network activity following GABAA receptor modulation. In this study we have used whole-head magnetoencephalography to characterize neuronal network activity, at rest and during visually cued finger abductions, in unilaterally symptomatic PD and age-matched control participants. Recordings were then repeated following administration of sub-sedative doses of the hypnotic drug zolpidem (0.05mg/kg), which binds to the benzodiazepine site of the GABAA receptor. A beamforming based 'virtual electrode' approach was used to reconstruct oscillatory power in the primary motor cortex (M1), contralateral and ipsilateral to symptom presentation in PD patients or dominant hand in control participants. In PD patients, contralateral M1 showed significantly greater beta power than ipsilateral M1. Following zolpidem administration contralateral beta power was significantly reduced while ipsilateral beta power was significantly increased resulting in a hemispheric power ratio that approached parity. Furthermore, there was highly significant correlation between hemispheric beta power ratio and Unified Parkinson's Disease Rating Scale (UPDRS). The changes in contralateral and ipsilateral beta power were reflected in pre-movement beta desynchronization and the late post-movement beta rebound. However, the absolute level of movement-related beta desynchronization was not altered. These results show that low-dose zolpidem not only reduces contralateral beta but also increases ipsilateral beta, while rebalancing the dynamic range of M1 network oscillations between the two hemispheres. These changes appear to underlie the symptomatic improvements afforded by low-dose zolpidem.


Asunto(s)
Ritmo beta/fisiología , Sincronización de Fase en Electroencefalografía/fisiología , Agonistas de Receptores de GABA-A/farmacología , Corteza Motora/fisiopatología , Enfermedad de Parkinson/fisiopatología , Piridinas/farmacología , Receptores de GABA-A/efectos de los fármacos , Anciano , Ritmo beta/efectos de los fármacos , Sincronización de Fase en Electroencefalografía/efectos de los fármacos , Femenino , Agonistas de Receptores de GABA-A/administración & dosificación , Humanos , Magnetoencefalografía , Masculino , Persona de Mediana Edad , Corteza Motora/efectos de los fármacos , Piridinas/administración & dosificación , Índice de Severidad de la Enfermedad , Zolpidem
4.
Neuroimage ; 56(3): 1506-10, 2011 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-21320607

RESUMEN

At rest, the primary motor cortex (M1) exhibits spontaneous neuronal network oscillations in the beta (15-30 Hz) frequency range, mediated by inhibitory interneuron drive via GABA-A receptors. However, questions remain regarding the neuropharmacological basis of movement related oscillatory phenomena, such as movement related beta desynchronisation (MRBD), post-movement beta rebound (PMBR) and movement related gamma synchronisation (MRGS). To address this, we used magnetoencephalography (MEG) to study the movement related oscillatory changes in M1 cortex of eight healthy participants, following administration of the GABA-A modulator diazepam. Results demonstrate that, contrary to initial hypotheses, neither MRGS nor PMBR appear to be GABA-A dependent, whilst the MRBD is facilitated by increased GABAergic drive. These data demonstrate that while movement-related beta changes appear to be dependent upon spontaneous beta oscillations, they occur independently of one other. Crucially, MRBD is a GABA-A mediated process, offering a possible mechanism by which motor function may be modulated. However, in contrast, the transient increase in synchronous power observed in PMBR and MRGS appears to be generated by a non-GABA-A receptor mediated process; the elucidation of which may offer important insights into motor processes.


Asunto(s)
Corteza Motora/fisiología , Movimiento/fisiología , Red Nerviosa/fisiología , Ácido gamma-Aminobutírico/fisiología , Adulto , Ritmo beta , Sincronización Cortical , Interpretación Estadística de Datos , Diazepam/farmacología , Electroencefalografía , Moduladores del GABA/farmacología , Humanos , Interneuronas/efectos de los fármacos , Interneuronas/fisiología , Magnetoencefalografía , Masculino , Persona de Mediana Edad , Corteza Motora/efectos de los fármacos , Movimiento/efectos de los fármacos , Red Nerviosa/efectos de los fármacos , Receptores de GABA-A/efectos de los fármacos
5.
Clin Obes ; 1(4-6): 184-8, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25585908

RESUMEN

Prader-Willi syndrome (PWS) is a multifaceted developmental disorder most commonly associated with extreme hyperphagia and life-threatening obesity. PWS is a genetic disorder of imprinting with almost all cases occurring spontaneously. Behavioural and imaging studies have shown that obesity in PWS arises from overeating driven by a faulty satiety mechanism which manifests as an almost permanent state similar to starvation. With no available treatments, management of the eating behaviour is the only option and has two main strategies: restrict access to food and distract thoughts from food. In this mini review, which we have aimed at clinicians, we outline the main aspects of PWS including genetics, development of the eating behaviour and best practice approaches to management.

6.
Int J Obes (Lond) ; 35(2): 188-97, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20680019

RESUMEN

Prader-Willi Syndrome (PWS) is a genetically determined neurodevelopmental disorder associated with mild to moderate intellectual disability, growth and sex-hormone deficiencies and a propensity to overeat that leads to severe obesity. The PWS phenotype changes from an early disinterest in food to an increasing pre-occupation with eating and a failure of the normal satiety response to food intake. The prevention of severe obesity is primarily through strict control of access to food and it is this aspect that most limits the independence of those with PWS. This review considers the eating disorder in PWS, specifically how the as yet uncertain genetics of the syndrome and the transition from the early to the later phenotype might account for the later hyperphagia. On the basis of behavioural and imaging studies, a failure of satiety and excessive activation of neural reward pathways have both been suggested. We speculate that the overeating behaviour, consequent upon one or other of the above, could either be due to a direct effect of the PWS genotype on the feeding pathways of the hypothalamus or a consequence of prenatal changes in the regulation of genes responsible for energy balance that sets a high satiation threshold. Understanding the overeating in PWS will lead to more focused and successful management and ultimately, treatment of this life-threatening behaviour.


Asunto(s)
Conducta Alimentaria/fisiología , Hiperfagia/fisiopatología , Obesidad/prevención & control , Síndrome de Prader-Willi/fisiopatología , Respuesta de Saciedad/fisiología , Femenino , Humanos , Hiperfagia/etiología , Hiperfagia/genética , Masculino , Obesidad/complicaciones , Obesidad/genética , Síndrome de Prader-Willi/complicaciones , Síndrome de Prader-Willi/genética , Recompensa
7.
Kidney Int ; 70(4): 771-80, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16820797

RESUMEN

Although renal osteodystrophy and vitamin D analogs may be related to survival in maintenance hemodialysis (MHD) patients, most studies have examined associations between baseline values and survival without accounting for variations in clinical and laboratory measures over time. We examined associations between survival and quarterly laboratory values and administered paricalcitol in a 2-year (July 2001-June 2003) cohort of 58,058 MHD patients from all DaVita dialysis clinics in USA using both time-dependent Cox models with repeated measures and fixed-covariate Cox models with only baseline values. Whereas hypercalcemia and hyperphosphatemia were robust predictors of higher death risk in all models, the association between serum calcium and mortality was different in time-varying models. Changes in baseline calcium and phosphorus values beyond the Kidney Disease Outcome Quality Initiative recommended targets were associated with increased mortality. Associations between high serum parathyroid hormone and increased death risk were masked by case-mix characteristics of MHD patients. Time-varying serum alkaline phosphatase had an incremental association with mortality. Administration of any dose of paricalcitol was associated with improved survival in time-varying models. Controlling for nutritional markers may introduce overadjustment bias owing to their strong collinearity with osteodystrophy surrogates. Whereas both time-dependent and fixed-covariate Cox models result in similar associations between osteodystrophy indicators and survival, subtle but potentially clinically relevant differences between the two models exist, probably because fixed models do not account for variations of osteodystrophy indices and changes in medication dose over time.


Asunto(s)
Trastorno Mineral y Óseo Asociado a la Enfermedad Renal Crónica/sangre , Enfermedades Renales/sangre , Enfermedades Renales/terapia , Diálisis Renal/mortalidad , Anciano , Fosfatasa Alcalina/sangre , Calcio/sangre , Trastorno Mineral y Óseo Asociado a la Enfermedad Renal Crónica/tratamiento farmacológico , Trastorno Mineral y Óseo Asociado a la Enfermedad Renal Crónica/etiología , Trastorno Mineral y Óseo Asociado a la Enfermedad Renal Crónica/mortalidad , Ergocalciferoles/uso terapéutico , Femenino , Humanos , Enfermedades Renales/complicaciones , Masculino , Persona de Mediana Edad , Análisis Multivariante , Hormona Paratiroidea/sangre , Fósforo/sangre , Valor Predictivo de las Pruebas , Modelos de Riesgos Proporcionales , Factores de Riesgo , Análisis de Supervivencia , Factores de Tiempo
8.
Anat Rec ; 216(4): 516-20, 1986 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-3799998

RESUMEN

In this report we quantitated ultrastructural changes in two cytologically distinct secretory cell populations from the rabbit endocervix. Type I and type II cells from estrous animals differ only in the presence of one or more empty cytoplasmic vacuoles in type II cells. Comparing type II cells from 5-day pseudopregnant (PSP) rabbits with type II cells from estrous controls, there is no increase (P greater than .05) in the average vacuole volume. When type I and type II cells from PSP animals are compared to cells from estrous controls, there is a decrease (P less than .01) in the average cell volume, a decrease (P less than .01) in the average nuclear volume, and a decrease (P less than .01) in the average granule volume. This reduction in the granule content of secretory endocervical cells was correlated with a dramatic decrease in protein glycosylation into the microsomal fraction. Serum estradiol concentrations for estrous (13.7 +/- 1.0 pg/ml) and PSP (18.1 +/- 1.5 pg/ml) animals were comparable. However, the 36-fold increase in serum progesterone concentrations for PSP (12.04 +/- 1.7 ng/ml) animals compared to estrous (0.33 +/- 0.1 ng/ml) animals may be responsible for the decrease in protein glycosylation.


Asunto(s)
Cuello del Útero/citología , Animales , Recuento de Células , Núcleo Celular/ultraestructura , Cuello del Útero/metabolismo , Cuello del Útero/ultraestructura , Células Epiteliales , Epitelio/ultraestructura , Estro , Femenino , Glicoproteínas/metabolismo , Microscopía Electrónica , Ovariectomía , Seudoembarazo/metabolismo , Seudoembarazo/patología , Conejos
9.
Steroids ; 46(4-5): 915-27, 1985.
Artículo en Inglés | MEDLINE | ID: mdl-2944253

RESUMEN

Uteri and cervices were obtained from estrous rabbits (controls) and from rabbits 24 h or 7 days after a single intramuscular injection of medroxyprogesterone acetate (MPA; 2.14 mg/kg). Estrogen and progesterone receptor concentrations were measured by Scatchard analysis, cell-free DNA synthesis was measured by (3H)-TTP incorporation, and tissue sections were examined histologically. The uterine endometrium underwent marked changes in histology, including extensive infoldings of the mucosal surface, glands were continuous into crypts and secretory epithelial cells were noted. In addition, total estrogen receptor content and DNA synthesis were decreased. In contrast, there was no significant change in the histology of the endocervical epithelial-stromal complex, and total estrogen receptor remained constant. However, DNA synthesis in the endocervix was decreased. Thus we conclude that: DNA synthesis is not linked to changes in estrogen receptor in the endocervix; and differential effects of progestogen on the estrogen receptor system occur coincident with different morphological responses within two target tissues from the same animal.


Asunto(s)
Cuello del Útero/efectos de los fármacos , Medroxiprogesterona/análogos & derivados , Receptores de Estrógenos/metabolismo , Receptores de Progesterona/metabolismo , Útero/efectos de los fármacos , Animales , Núcleo Celular/metabolismo , Citosol/metabolismo , ADN/biosíntesis , Endometrio/metabolismo , Femenino , Medroxiprogesterona/farmacología , Acetato de Medroxiprogesterona , Conejos
11.
12.
Hum Pathol ; 12(7): 597-604, 1981 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-7024099

RESUMEN

We present the clinical and pathologic data from two patients with rapidly progressive glomerulonephritis in whom the unusual combination of antiglomerular basement membrane antibody and immune complex disease was observed. In both patients the diagnosis of antiglomerular basement membrane disease was confirmed by renal tissue immunofluorescence and by positive assays for circulating antiglomerular basement membrane antibody. Ultrastructural studies revealed membranous nephropathy in one patient. Our data from this patient suggested evolution of pre-existing membranous nephropathy into antiglomerular basement membrane disease. In the second patient electron microscopy of renal tissue demonstrated numerous subendothelial, mesangial, and subepithelial deposits. It was impossible to ascertain in this patient whether antiglomerular basement membrane antibody or immune complex mediated injury was the primary pathogenetic event. Our data provide additional evidence for the rare clinical appearance of concurrent antiglomerular basement membrane and immune complex disease. Although the coexistence in both patients of antiglomerular basement membrane disease with immune complexes may have been coincidental, we think that this is unlikely. Rather our data suggest that the two mechanisms are causally related and that either one could have been the primary disease process.


Asunto(s)
Anticuerpos/inmunología , Complejo Antígeno-Anticuerpo/fisiología , Glomerulonefritis/inmunología , Glomérulos Renales/inmunología , Anciano , Membrana Basal/inmunología , Biopsia , Técnica del Anticuerpo Fluorescente , Glomerulonefritis/patología , Humanos , Riñón/ultraestructura , Masculino , Microscopía , Microscopía Electrónica
13.
Clin Nephrol ; 12(4): 178-85, 1979 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-389506

RESUMEN

Renal failure is a common cause of death in patients with progressive systemic sclerosis (PSS). The present paper describes two patients with chronic renal failure secondary to PSS whom we have treated by a combination of chronic hemodialysis and renal transplantation. Also reviewed are reports of six additional patients who have undergone renal transplantation. We conclude that chronic hemodialysis and renal transplantation are successful life-sustaining treatment modalities in some patients with end-stage renal disease due to PSS.


Asunto(s)
Fallo Renal Crónico/etiología , Trasplante de Riñón , Riñón/patología , Esclerodermia Sistémica/complicaciones , Adulto , Femenino , Humanos , Fallo Renal Crónico/patología , Fallo Renal Crónico/terapia , Masculino , Persona de Mediana Edad , Enfermedad de Raynaud/complicaciones , Recurrencia , Diálisis Renal , Esclerodermia Sistémica/patología , Trasplante Homólogo
14.
South Med J ; 72(2): 162-5, 1979 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-424794

RESUMEN

A 27-year-old man, a known heroin addict with previously diagnosed nephrotic syndrome, had a percutaneous renal biopsy for recurrent proteinuria. The biopsy revealed a glomerular lesion compatible with focal sclerosing hephropathy. The renal interstitium also demonstrated numerous active granulomas characterized by the presence of both multilamellated basophilic material and areas of unstained fibrillar material. These findings represent a previously undescribed complication of parenteral heroin abuse--renal granuloma formation.


Asunto(s)
Granuloma/etiología , Dependencia de Heroína/complicaciones , Enfermedades Renales/etiología , Nefritis Intersticial/etiología , Adulto , Granuloma/patología , Dependencia de Heroína/patología , Humanos , Riñón/patología , Enfermedades Renales/patología , Masculino , Nefritis Intersticial/patología
15.
Clin Nephrol ; 10(5): 191-5, 1978 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-729214

RESUMEN

Adverse reactions to phenothiazines have not been commonly recognized in patients with chronic renal failure. We wish to report a characteristic acute psychosis as a complication of phenothiazine use in such individuals. Four patients with chronic renal failure requiring hemodialysis were given doses of chlorpromazine ranging from 100--1000 mg over time intervals varying from 2--7 days. All developed extreme restlessness, auditory and visual hallucinations, and episodes of belligerent behavior. A fifth patient treated with promethazine developed a similar psychosis. Each became ill shortly after the initiation of phenothiazine therapy. All improved slowly after cessation of the drug. Hemodialysis in four patients did not appear to affect the course of the illness. The use of phenothiazines in patients with chronic renal failure is cautioned.


Asunto(s)
Clorpromazina/efectos adversos , Fallo Renal Crónico/complicaciones , Prometazina/efectos adversos , Psicosis Inducidas por Sustancias/etiología , Anciano , Humanos , Masculino , Persona de Mediana Edad , Diálisis Renal
16.
JACEP ; 7(3): 96-8, 1978 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-633683

RESUMEN

Specific emergencies occur in patients maintained on hemodialysis that often require evaluation and treatment in the emergency department, including infection of the access, cardiovascular disease, blood pressure abnormalities, pericarditis, cardiac arrhythmias and headache. Specific recommendations for treatment are presented.


Asunto(s)
Urgencias Médicas , Fallo Renal Crónico/terapia , Diálisis Renal , Derivación Arteriovenosa Quirúrgica/efectos adversos , Humanos , Hipertensión/etiología , Hipotensión/etiología , Enfermedades del Sistema Nervioso/etiología , Diálisis Renal/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...